The South Africa Continuous Glucose Monitoring Market size is estimated at USD 17.61 million in 2024, and is expected to reach USD 31.47 million by 2029, growing at a CAGR of 12.31% during the forecast period (2024-2029).



Patients with diabetes infected with COVID-19 experienced elevated blood glucose, abnormal glucose variability, and diabetic complications. The Western Cape Provincial Health Department’s data on COVID-19 fatalities suggested that people with diabetes were more likely to die from COVID-19 than any other high-risk group. The provincial health department estimated that out of every 100 people within the public healthcare sector who died from COVID-19, 52 had diabetes. While new-onset hyperglycemia and new-onset diabetes have been increasingly recognized in the context of COVID-19 and have been associated with worse outcomes. To avoid aggravation, a patient’s blood glucose should be monitored and maintained regularly.



The measurement of blood glucose is necessary to keep the blood glucose levels within a specified target range. Continuous glucose monitoring (CGM) helps understand the effectiveness of blood glucose metabolism and guides in achieving optimal glucose control within the body. Over time, the readings provided the patients and their health professionals with the information required to determine the best management strategy for diabetes.



Furthermore, the current continuous glucose monitoring can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays. The newest CGM models, the Abbott Freestyle Libre 3 and the Dexcom G7, overcame many technical barriers. Technological advances such as Eversense E3 CGMs have significantly improved the ability of providers and patients to manage diabetes, thereby enhancing the market prospects in the years to come.



South Africa Continuous Glucose Monitoring Market Trends



Rising Diabetes Prevalence in South Africa is anticipated to boost the market studied



In South Africa, the diabetes population is expected to increase with a CAGR greater than 2.5% over the forecast period.



According to IDF Diabetes Atlas 2021, one in nine adults in South Africa is living with diabetes. The diabetes prevalence in South Africa has reached 11.3%. The cost of diabetes-related health expenditure has risen to 1,700 USD per person, which is estimated to be around 7.2 billion USD. In South Africa, diabetes is the fastest-growing disease. The prevalence of diabetes is growing among all ages in South Africa, which can be attributed to the increasingly obese population, along with an unhealthy diet and a sedentary lifestyle.



South Africa is working towards educating citizens and encouraging healthy decision-making. The recent preventative measure taken by the South African government is the implementation of a sugar tax. By charging more for sugary drinks and foods, the government is fighting obesity and helping citizens make more conscious decisions. South Africa launched a Diabetes Prevention Programme (DPP). The DPP aims to integrate intervention treatments for at-risk individuals.



The World Health Assembly Resolution 2022 recommends the integration of prevention and treatment of diabetes into primary health services, the development of pathways for increase in access to insulin, promotion of convergence and harmonization of regulatory requirements for diabetes medicines and technologies, and improved diabetes monitoring and surveillance. Furthermore, it involves the WHO to advise the Member States to ensure the uninterrupted treatment of people living with diabetes in humanitarian emergencies.



Therefore, the studied market is anticipated to witness growth over the analysis period due to rising prevalence and increasing awareness through government initiatives.



The Sensors Segment is Expected to Hold the Highest Share Over the Forecast Period



The sensors segment is expected to register a CAGR of 15.2% over the forecast period.



Continuous glucose monitoring devices are automated glucose monitoring systems that consist of a small device that can be worn on the body and held on by an adhesive patch. The sensor part of the device has a cannula that is inserted into the top layer of skin and uses samples of interstitial fluid to check glucose levels. Sensors are connected to a transmitter that can send data wirelessly to a dedicated mobile receiving device or smartphone. Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Sensors are the most important part of continuous glucose monitoring devices.



Researchers are trying to find and develop alternatives to electrochemical-based glucose sensors and create more affordable, minimally invasive, and user-friendly CGM sensors. Optical measurement is a promising platform for glucose sensing. Some technologies have been reported to have high potential in continuous glucose sensing, including spectroscopy, fluorescence, holographic technology, etc. Eversense, a CGM sensor based on fluorescence sensing developed by Senseonics company has a much longer lifespan in comparison with electrochemical sensors. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.



CGMs-insulin pump combinations are used to automatically adjust insulin delivery based on a patient’s glucose levels. Medtronic has a few combination systems on the market, including the MiniMed 630G system, the 670G system, and the Paradigm Revel. The MiniMed 630G system and Paradigm Revel are both approved for use by adults and children from the age of 16 years, and the MiniMed 670G system is approved for use by adults and children aged 14 years and older with T1D. The advent of such new technologies is likely to drive segment growth during the forecast period.



South Africa Continuous Glucose Monitoring Industry Overview



The South Africa Continuous Glucose Monitoring Market is consolidated, with few significant players. There have been constant innovations driven by manufacturers such as Abbott, Dexcom, Medtronic, etc. while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.



Additional Benefits:



  • The market estimate (ME) sheet in Excel format

  • 3 months of analyst support